FROM PUBLIC EVENTS · 2026-11-18

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Early clinical · first deals Has dosed the first patient in a US Phase 1 trial of its CD123-targeting DAC, ORM-1153.

  • Announced first patient dosing in the US Phase 1 trial of ORM-1153. Source

Roles often seen at this stageResearch & development · Clinical & PV · Regulatory affairs

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-18

Orum Therapeutics

A clinical-stage biotech developing degrader-antibody conjugates (DACs) that attach protein degraders to antibodies.

ORM-1153

Phase 1

A DAC pairing a CD123-targeting antibody with a GSPT1 degrader, in a US Phase 1 trial planned for about 42 patients with relapsed or refractory AML and other blood cancers.

DAC platform

Technology platform

The company's core technology combining antibodies with degraders for cell-selective protein degradation.

Completion reported

Dosed the first patient in the US Phase 1 trial of ORM-1153.

Official role guide

Orum Therapeutics careers

Current availability unconfirmed

Observed 2026-11-18

Work
Unconfirmed — The official careers page was found, but postings and duties were not read in this check.
Experience & requirements
Unconfirmed — Requirements were not checked on the official careers page.

Information from a role guide does not establish a current vacancy.

Sources & coverage 2

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. Orum Therapeutics ↗Orum Therapeutics · Published Date unconfirmed · Sources checked 2026-11-18 · Original unavailable
  2. 오름테라퓨틱 DAC 후보물질 ORM-1153 임상 1상 첫 환자 투여 ↗한국경제 · Published 2026-10-14 · Sources checked 2026-11-18 · Original unavailable